Previous case-control studies showed that genetic variation in the fibrinogen gamma gene (FGG) increased the risk for VT in adults. We investigated the association between the fibrinogen alpha (FGA) and FGG haplotypes, the Factor V Leiden -mutation and pediatric VT and thromboembolic stroke (TS) in two independent study samples. Association analysis revealed that the FGA-H1, and FGG-H2 haplotypes were significantly overtransmitted to VT patients P=0.05; FGG: H2, P=0.032). In contrast, the FGG-H3 haplotype was undertransmitted (P=0.0216). In an independent study sample, FGA-H1 (P=0.0085) and FGG-H2 
Introduction
Population-based association studies in adults have provided sound evidence for the association of fibrinogen levels with arterial disease, and for the association of fibrinogen gene variations with fibrinogen levels. For example, abnormalities of fibrinogen levels have been reported to affect risk for deep vein thrombosis (VT), particularly in the elderly 1, 2 . However, evidence for the association of disease and fibrinogen gene polymorphisms thought to affect fibrinogen levels is weak 3, 4 . One of the mechanisms by which changes in the fibrin network may contribute to an increased VT risk may hinge upon the composition of circulating total fibrinogen levels, particularly the fraction of fibrinogen γ ' levels, which in part is influenced by genetic variants residing in the fibrinogen gamma (FGG) gene located on the long arm of human chromosome 4 (4q28). A recent study investigating the role of genetic variants in predisposing to VT implicated genetic variants in fibrinogen alpha (FGA) and FGG genes as genetic determinants for VT through the reduction of circulating plasma fibrinogen γ ' levels 5 .
In this study, homozygous carriership of a FGG risk haplotype (FGG-H2) was associated with an increased risk for VT (OR 2.4, 95% C.I. 1.5-3.9), and furthermore, reduced fibrinogen [ 7.,8,9 ] ). Because of the low incidence of pediatric VT in the general population (0.07-0.14 / 10,000 population children; ~5 / 10,000 hospital admissions of children), studies addressing the impact of genetic modifiers of thrombosis on the incidence of pediatric VT are limited by the relatively small number of patients and, therefore, often remain inconclusive. Metaanalyses of available data suggest that inherited thrombophilic mutations in coagulation factors identified in adult patients (i.e. factor V (FV) Leiden G1691A, prothrombin G20210A, deficiency of protein S, protein C, and antithrombin) are also the most common genetic determinants of pediatric first VT and ischemic stroke [ 7, 9, 10 ].The contribution of fibrinogen gene variation to the incidence of VT in children, and the association with the relative abundance of fibrinogen γ chain isoforms in plasma are unknown. The goal of the current study was to
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Patients and Methods
In the German study center Muenster, plasma and DNA samples of 244 families of children with VT ( Fig.1) and sisters and available parents were enrolled. Premature birth (< 36 gestational weeks), patients older than 18 years at onset, and children with a first ischemic stroke of vascular origin were excluded. In addition, children with missing parents, families with non-paternity, children lost to follow-up and patients without parental consent were excluded. Further exclusion criteria were ongoing liver, renal, or inflammatory diseases, malignancies, and concurrent treatment regimens known to influence fibrinogen levels. In-and exclusion criteria are shown in Fig 1. The replication study sample with pediatric thromboembolic stroke and criteria for group assignment to vascular stroke were described in detail elsewhere 11, 12 .
Blood sample collection
Blood sample collection from patients was done in the morning after a 12-hour fasting period (infants 4-6 hours); samples were drawn by peripheral venipuncture into plastic tubes containing 1/10 by volume of 3.8% trisodium citrate (Sarstedt) and were immediately placed on melting ice. The blood samples from patients were collected 6-12 months after the acute thrombotic event, and at least 6 weeks apart from anticoagulation. Platelet-poor plasma was prepared by centrifugation at 3000 g and 4° C for 2x20 minutes, aliquoted in polystyrene tubes, stored at -70° C and thawed immediately before assay. DNA extraction was performed by a spin column procedure (Qiagen) according to the manufacturer's instructions. 4 . Genotyping was performed using the TaqMan allelic discrimination method on a 384-well H7900 (Applied Biosystems, Foster City, USA) using 2ng of genomic DNA. For quality control each plate contained 8 positive CEPH-controls and 8 no-template controls (NTCs) to ensure genotyping accuracy. Genotyping efficiency was >99.5%. In addition, presence or absence of the Factor V Leiden mutation was determined using standard laboratory techniques 15, 16 .
Fibrinogen and fibrinogen gamma

Statistical analysis
Hardy-Weinberg-Equilibrium for each htSNP was tested using χ 2-analysis across all samples. Family-based association was determined using the transmission disequilibrium test (TDT) 17 in 244 trios comprising unaffected parents and the affected child; haplotypes were inferred using the Expectation Maximization Algorithm as implemented in Haploview (Vs. For correlation analyses between associated FGG haplotypes and fibrinogen γ ' to total fibrinogen levels in the affected children, the individual haplotypes were reconstructed based on phase, since genotype information was available for both parents and the affected child.
Distribution of total fibrinogen and fibrinogen γ ' levels were assessed using the KolmogorovSmirnov-Test for normalcy to ensure a normal distribution as a prerequisite for parametric analyses. Correlation analyses was performed using one-way analysis of variance (ANOVA), followed by the appropriate post-hoc test (student's T-test). P-values were adjusted for multiple testing using the Bonferroni method (Haplotypes, FV Leiden carriership (yes/no), 2 phenotypes = 8 comparisons).
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Results
Association between fibrinogen haplotypes and pediatric VT
Genotyping of 244 families for VT (786 individuals) showed that the selected seven htSNPs identified the 4 most common haplotypes in FGG and the 5 most common haplotypes in FGA, and thus captures 97.5% of the genetic variation present in haplotypes at a frequency >1%. (Fig.2a) . For all SNPs, the distribution of the genotypes was in Hardy-WeinbergEquilibrium and similar to those reported by previous studies 5, 4 . Consistent with previous observations 5, 4 , a high degree of linkage disequilibrium was detected between FGA and FGG (Fig.2b) . However, in our study recombination events were detected between rs2070011 and rs1049636 (D'=0.1) that may affect haplotype structure of the fibrinogen gene cluster
Single-point TDT identified three significantly associated SNPs with VT, rs6050
[Thr312Ala] (ratio of transmissions to non-transmissions of the overtransmitted allele (T:U) haplotype was significantly under-transmitted to affected offspring in our pediatric VT cohort and might thus represent a protective haplotype.
The strong linkage disequilibrium detected between the FGA-H1 and FGG-H2 risk haplotypes ( Fig. 2b ) raised the possibility that these haplotypes are largely co-inherited. Phaseadjusted haplotype analysis showed indeed that a recombination event between FGA-H1 and FGG-H2 had occurred in less than 10% of children.
Replication of association in thrombo-embolic pediatric stroke
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2=0.00, P=0.993).
To increase the statistical power of the study, we examined whether combining the VT and TS study populations would strengthen or weaken the association of this haplotype with thromboembolic disease. Given the allele frequency of 0.41 for the risk allele (e.g. rs6050 or rs2066861) and a genotype relative risk (GRR) of 1.5 and 2.0 for heterozygous and homozygous risk allele carriers, respectively, combining all 512 families from both study samples is predicted to enhance the statistical probability to detect association at an α=0.05 through TDT analysis to 79.8%. Single-point TDT analysis of the combined pediatric VT and TS study This analysis indicates that the VT-risk haplotypes FGA-H1 and FGG-H2 also modify the incidence of TS. Conversely, association analysis of FGG-H3 and FGG-H4 produces divergent outcomes in VT (H3 protective/under-transmitted; H4 neutral) and TS patients (H3 neutral; H4 protective/under-transmitted). Homozygous carriership of the FGG-H2 risk haplotype was associated with the lowest fibrinogen γ ' content, in both absolute and relative terms (Table 3a) . In compound heterozygous carriers of one H2 allele and any of the other three FGG haplotypes, absolute and relative γ' levels were on average higher than in H2/H2 homozygotes, but lower than in non-H2 carriers (Table 3b ). Homozygous carriers of the (under-transmitted) FGG H3 haplotype show the highest relative fibrinogen γ ' content, in part due to overall lower total fibrinogen levels.
Genetic Interaction between FV
A similar positive correlation between FGG-H3 carrier status and relative abundance of γ' fibrinogen (P=0.000032, Bonferroni-corrected P=0.00025) is seen in compound heterozygotes carrying one H3 allele and one H2 allele. Congruent with studies by others 5, 19 , carriership for any risk haplotype was associated weakly, if at all, with total plasma fibrinogen.
These outcomes are consistent with the notion that the VT and TS risk allele FGG-H2 is associated with a lower γ'/total fibrinogen ratio, independent of absolute fibrinogen levels.
Discussion
Results of the current genetic study of 512 families with at least one child affected by childhood-onset VT or TS indicate that carriership for the FGG H2 haplotype is significantly associated with pediatric VT as well as TS. Measurements of total fibrinogen and the γ' isoform of FGG suggest a gene dose effect of FGG alleles on the γ':fibrinogen ratio, independent of absolute plasma fibrinogen levels, with highest relative γ' levels in homozygous FGG-H3 carriers, and lowest relative γ' levels in children homozygous for the FGG-H2 risk allele.
These data are congruent with earlier findings characterizing the FGG H2 allele and associated diminished relative levels of γ' fibrinogen as a risk factor for VT in adults 5, 19 . While a recent case-control study of adults failed to detect an association of the FGG H2 risk haplotype with VT this lack of association might be ascribed to the relatively small sample size (124 cases and 125 controls) and therefore most likely constitute a type II error (missed association). The current analysis further detected a statistically significant negative correlation of FGG-H3 carriership with VT. This finding dovetails evidence from one previous study 20 that the FGG H3 haplotype may constitute a protective factor for ischemic stroke. We note, that in the original study by Uitte de Willige 5 the FGG H3 haplotype was also observed more frequently in controls than in VT patients, and was associated with a decreased VT risk (OR 0.8 95% CI:0.6-1.0).
In aggregate, these findings suggest that the plasma γ'/fibrinogen ratio (1) moderately alters the population risk of VT and ischemic stroke, and (2) showed that Ala312 fibrin fibers are thicker, produce clots with reduced elasticity, and exhibit a higher degree of cross-linking mediated by factor XIII 24 .
The high degree of linkage disequilibrium between FGG and FGA gene haplotypes confounds the assignment of disease risk to specific alleles, and in general complicates establishing the association between genetic variations in the fibrinogen gene locus, level and composition of fibrinogen. Specifically, studies examining the effect of putative FGG H2 risk haplotype associated with diminished γ' chain production relative to total fibrinogen, recognized that this haplotype is in a significant portion of individuals co-inherited with a second polymorphism located in the FGA gene (FGA Thr312Ala; rs6050). We show that the same is true in our pediatric study population, where the FGA H1 variant is co-inherited with the FGG H2 risk haplotype in 188 of 200 children. These observations highlight that FGA-H1 (Ala312) and FGG-H2 (low γ'/γ ratio) are in the majority of individuals co-inherited. As briefly discussed in two previous studies 5, 20 , this implies, first, that population-based calculations of the risk conferred by these haplotypes must consider haplotype combinations, rather than a model of independent risk factors. Indeed, comparison of patients carrying the combined FGA- Recent experiments in mice genetically altered to produce a human γ' fibrin variant capable of high-affinity interaction with thrombin provided direct experimental evidence that γ'/γA fibrin exerts an anticoagulant effect that ameliorates the prothrombotic effect of the FV Leiden mutation 25 . Stratification of families according to FV Leiden -carriership showed that the genetic risk attributable to FGA and FGG variants is influenced by the presence or absence of the FV Leiden -mutation: the association of FGG-H2 with a lower γ'/fibrinogen ratio -and with borderline significance (p=0.0566) also of absolute γ' levels -was clearly detectable in both FV Leiden -negative and positive individuals, and was again independent of total fibrinogen levels (Table 3B ). The loss of genetic association with disease might be due to a lack of statistical power to detect a weak association of FGA/FGG haplotypes in the presence of a comparably strong risk factor, such as the FV Leiden -mutation. However, a different SNP (rs1039636; data not shown) was associated with VT and/or TS exclusively in FV Leiden carriers, but not in FV Leiden -negative families, indicating that our study was sufficiently powered to detect such positive interactions.
Although, the design of the current study inherently does not enable calculations of odds ratios, estimates of the genotype relative risk (GRR) are consistent with results from population-based association studies that estimate the risk conferred by FGA-H1/FGG-H2
carriership in the range of 1.1-1.8. The FGA-H1/FGG-H2 risk alleles therefore only modestly affect overall disease incidence, and are in all likelihood not informative for predicting thrombosis risk in a given individual. However, genotyping for carriership of the FGA-H1/FGG-H2 alleles could in theory identify a subpopulation of patients whose blood clots exhibit properties distinct from those formed in non-carriers of these alleles. The overall bio-
produced in FGA H1 carriers are remarkably similar to the biochemical effects predicted for diminished levels of γ' fibrinogen on clot structure, including partial resistance to fibrinolysis 26 , enhanced mechanical clot stiffness, and increased fiber diameter. In addition, thrombin bound to the γ'-isoform is relatively resistant to anticoagulant treatment with heparin 27, 28 . Thus, in vivo formed clots in FGA-H1/FGG-H2 individuals might combine, possibly in an exaggerated manner, the properties of clots documented ex vivo for γ' fibrin or Ala312 fibrin. Fibrin γ'-chains not only interact with thrombin, but also contain a nearby binding site for fXIII zymogen. The interaction of fibrin-associated fXIII and thrombin may contribute to the altered clot characteristics of fibrin with a high content of γ' chains by altering the kinetics of fXIII activation by thrombin 29, 30 . We note in this context that the fXIII Leu34 variant, which has been identified as a protective trait in thrombotic disorders, produces similar alterations in fibrin structure as high levels of γ' fibrin 29 . In vitro experiments with purified fibrinogen suggest that an increased rate of thrombin generation -as it is likely to occur in FV Leiden carriers -may override the biochemical differences between the structures of Ala312 and Thr312 fibrin, or γA/γA and γ'/γA fibrin 31, 32, 33, 34 , providing a theoretical explanation how the FV Leiden -mutation might mitigate the risk conferred by
FGA-H1/FGG-H2.
Taken together, the effects of polymorphisms in fXIII, fibrinogen A-, and fibrinogen γ chain genes on thrombosis may converge on a common biochemical pathway that defines fibrin structure and susceptibility of formed fibrin to fibrinolysis. The broader significance of these findings for identifying patients at risk and the therapeutic approach to thrombosis remains to be investigated.
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